Mobile

To evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of Alzheimer’s disease

Update Il y a 4 ans
Reference: EUCTR2015-002715-15

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

- To assess the effects of CAD106 and CNP520, respectively, vs. placebo on Time-to-event, with event defined as a diagnosis of MCI due to AD or dementia due to AD, whichever occurs first during the course of the study. - To assess the effects of CAD106 and CNP520, respectively, vs. placebo on cognition as measured by the change from Baseline to Month 60 in the APCC test score.

Inclusion criteria

  • Alzheimer's disease

Links